Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line
Hepatocellular carcinoma is one of the most common causes of cancer-related deaths globally. Bioavailable, effective and safe therapeutic agents are urgently needed for cancer treatment. This study evaluated the metabolomics profiling, anti-proliferative and pro-apoptotic effects of strigol/albumin/...
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 2021-10, Vol.142, p.111960 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 111960 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 142 |
| creator | Al-Malki, Abdulrahman L Bakkar, Ashraf Huwait, Etimad A Barbour, Elie K Abulnaja, Kalid O Kumosani, Taha A Moselhy, Said S |
| description | Hepatocellular carcinoma is one of the most common causes of cancer-related deaths globally. Bioavailable, effective and safe therapeutic agents are urgently needed for cancer treatment. This study evaluated the metabolomics profiling, anti-proliferative and pro-apoptotic effects of strigol/albumin/chitosan nanoparticles (S/A/CNP) on HepG2 cell line. The diameter of S/A/CNP was (5 ± 0.01) nm. The IC
was 180.4 nM and 47.6 nM for Strigol1 and S/A/CNP, respectively, after incubation for 24 h with HepG2 cells. By increasing the concentration of S/A/CNP, there was chromatin condensation, degranulation in the cytoplasm and shrinking in cell size indicating pro-apoptotic activity. Metabolomics profiling of the exposed cells by LC/MS/MS revealed that S/A/CNP up-regulated epigenetic intermediates (spermine and spermidine) and down-regulated energy production pathway and significantly decreased glutamine (P |
| doi_str_mv | 10.1016/j.biopha.2021.111960 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2559430674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2559430674</sourcerecordid><originalsourceid>FETCH-LOGICAL-p257t-267e92cca3fee85532f5f611e582984682415cb31d09c68dda523c8fc1f350d63</originalsourceid><addsrcrecordid>eNpNkM9Kw0AYxBdRrFbfQGSPHmy6f7Kb5ChFW6HgQT2XL5svdstmN2YToa_gUxu1gqeZw2-GYQi54izhjOv5LiltaLeQCCZ4wjkvNDsiZ7xQbKYZy47_-Qk5j3HHGFNa5qdkIlOpRMbzM_L53Hf2LTg-B1cOjfVzs7V9iOCpBx9a6HprHEZaoekQIlKDztEPC6V1tt_fUuurwSCFNrRjzkYKvqLgeuxogz2UwYXGmkjbLtTW4cjTFbZLQQ14M0I_fc56vCAnNbiIlwedkteH-5fFarZ-Wj4u7tazVqisnwmdYSGMAVkj5kpJUatac44qF0We6lykXJlS8ooVRudVBUpIk9eG11KxSsspufntHRe9Dxj7TWPj9wrwGIa4EUoVqWQ6S0f0-oAOZYPVpu1sA91-8_ef_ALwI3ZH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2559430674</pqid></control><display><type>article</type><title>Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Al-Malki, Abdulrahman L ; Bakkar, Ashraf ; Huwait, Etimad A ; Barbour, Elie K ; Abulnaja, Kalid O ; Kumosani, Taha A ; Moselhy, Said S</creator><creatorcontrib>Al-Malki, Abdulrahman L ; Bakkar, Ashraf ; Huwait, Etimad A ; Barbour, Elie K ; Abulnaja, Kalid O ; Kumosani, Taha A ; Moselhy, Said S</creatorcontrib><description>Hepatocellular carcinoma is one of the most common causes of cancer-related deaths globally. Bioavailable, effective and safe therapeutic agents are urgently needed for cancer treatment. This study evaluated the metabolomics profiling, anti-proliferative and pro-apoptotic effects of strigol/albumin/chitosan nanoparticles (S/A/CNP) on HepG2 cell line. The diameter of S/A/CNP was (5 ± 0.01) nm. The IC
was 180.4 nM and 47.6 nM for Strigol1 and S/A/CNP, respectively, after incubation for 24 h with HepG2 cells. By increasing the concentration of S/A/CNP, there was chromatin condensation, degranulation in the cytoplasm and shrinking in cell size indicating pro-apoptotic activity. Metabolomics profiling of the exposed cells by LC/MS/MS revealed that S/A/CNP up-regulated epigenetic intermediates (spermine and spermidine) and down-regulated energy production pathway and significantly decreased glutamine (P < 0.001). These findings demonstrated that S/A/CNP has anti-proliferative, apoptotic effects and modulate energetic, and epigenetic metabolites in the hepatocellular carcinoma cell line (HepG2).</description><identifier>ISSN: 1950-6007</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2021.111960</identifier><identifier>PMID: 34352718</identifier><language>eng</language><publisher>France</publisher><subject>Apoptosis - drug effects ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Chitosan - chemistry ; Chromatography, Liquid ; Down-Regulation - drug effects ; Hep G2 Cells ; Humans ; Inhibitory Concentration 50 ; Lactones - administration & dosage ; Lactones - pharmacology ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Metabolomics ; Nanoparticles ; Particle Size ; Serum Albumin, Human - chemistry ; Tandem Mass Spectrometry ; Up-Regulation - drug effects</subject><ispartof>Biomedicine & pharmacotherapy, 2021-10, Vol.142, p.111960</ispartof><rights>Copyright © 2021. Published by Elsevier Masson SAS.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34352718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Malki, Abdulrahman L</creatorcontrib><creatorcontrib>Bakkar, Ashraf</creatorcontrib><creatorcontrib>Huwait, Etimad A</creatorcontrib><creatorcontrib>Barbour, Elie K</creatorcontrib><creatorcontrib>Abulnaja, Kalid O</creatorcontrib><creatorcontrib>Kumosani, Taha A</creatorcontrib><creatorcontrib>Moselhy, Said S</creatorcontrib><title>Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Hepatocellular carcinoma is one of the most common causes of cancer-related deaths globally. Bioavailable, effective and safe therapeutic agents are urgently needed for cancer treatment. This study evaluated the metabolomics profiling, anti-proliferative and pro-apoptotic effects of strigol/albumin/chitosan nanoparticles (S/A/CNP) on HepG2 cell line. The diameter of S/A/CNP was (5 ± 0.01) nm. The IC
was 180.4 nM and 47.6 nM for Strigol1 and S/A/CNP, respectively, after incubation for 24 h with HepG2 cells. By increasing the concentration of S/A/CNP, there was chromatin condensation, degranulation in the cytoplasm and shrinking in cell size indicating pro-apoptotic activity. Metabolomics profiling of the exposed cells by LC/MS/MS revealed that S/A/CNP up-regulated epigenetic intermediates (spermine and spermidine) and down-regulated energy production pathway and significantly decreased glutamine (P < 0.001). These findings demonstrated that S/A/CNP has anti-proliferative, apoptotic effects and modulate energetic, and epigenetic metabolites in the hepatocellular carcinoma cell line (HepG2).</description><subject>Apoptosis - drug effects</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Chitosan - chemistry</subject><subject>Chromatography, Liquid</subject><subject>Down-Regulation - drug effects</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><subject>Lactones - administration & dosage</subject><subject>Lactones - pharmacology</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Metabolomics</subject><subject>Nanoparticles</subject><subject>Particle Size</subject><subject>Serum Albumin, Human - chemistry</subject><subject>Tandem Mass Spectrometry</subject><subject>Up-Regulation - drug effects</subject><issn>1950-6007</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM9Kw0AYxBdRrFbfQGSPHmy6f7Kb5ChFW6HgQT2XL5svdstmN2YToa_gUxu1gqeZw2-GYQi54izhjOv5LiltaLeQCCZ4wjkvNDsiZ7xQbKYZy47_-Qk5j3HHGFNa5qdkIlOpRMbzM_L53Hf2LTg-B1cOjfVzs7V9iOCpBx9a6HprHEZaoekQIlKDztEPC6V1tt_fUuurwSCFNrRjzkYKvqLgeuxogz2UwYXGmkjbLtTW4cjTFbZLQQ14M0I_fc56vCAnNbiIlwedkteH-5fFarZ-Wj4u7tazVqisnwmdYSGMAVkj5kpJUatac44qF0We6lykXJlS8ooVRudVBUpIk9eG11KxSsspufntHRe9Dxj7TWPj9wrwGIa4EUoVqWQ6S0f0-oAOZYPVpu1sA91-8_ef_ALwI3ZH</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Al-Malki, Abdulrahman L</creator><creator>Bakkar, Ashraf</creator><creator>Huwait, Etimad A</creator><creator>Barbour, Elie K</creator><creator>Abulnaja, Kalid O</creator><creator>Kumosani, Taha A</creator><creator>Moselhy, Said S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202110</creationdate><title>Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line</title><author>Al-Malki, Abdulrahman L ; Bakkar, Ashraf ; Huwait, Etimad A ; Barbour, Elie K ; Abulnaja, Kalid O ; Kumosani, Taha A ; Moselhy, Said S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p257t-267e92cca3fee85532f5f611e582984682415cb31d09c68dda523c8fc1f350d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Apoptosis - drug effects</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Chitosan - chemistry</topic><topic>Chromatography, Liquid</topic><topic>Down-Regulation - drug effects</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><topic>Lactones - administration & dosage</topic><topic>Lactones - pharmacology</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Metabolomics</topic><topic>Nanoparticles</topic><topic>Particle Size</topic><topic>Serum Albumin, Human - chemistry</topic><topic>Tandem Mass Spectrometry</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Malki, Abdulrahman L</creatorcontrib><creatorcontrib>Bakkar, Ashraf</creatorcontrib><creatorcontrib>Huwait, Etimad A</creatorcontrib><creatorcontrib>Barbour, Elie K</creatorcontrib><creatorcontrib>Abulnaja, Kalid O</creatorcontrib><creatorcontrib>Kumosani, Taha A</creatorcontrib><creatorcontrib>Moselhy, Said S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Malki, Abdulrahman L</au><au>Bakkar, Ashraf</au><au>Huwait, Etimad A</au><au>Barbour, Elie K</au><au>Abulnaja, Kalid O</au><au>Kumosani, Taha A</au><au>Moselhy, Said S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2021-10</date><risdate>2021</risdate><volume>142</volume><spage>111960</spage><pages>111960-</pages><issn>1950-6007</issn><eissn>1950-6007</eissn><abstract>Hepatocellular carcinoma is one of the most common causes of cancer-related deaths globally. Bioavailable, effective and safe therapeutic agents are urgently needed for cancer treatment. This study evaluated the metabolomics profiling, anti-proliferative and pro-apoptotic effects of strigol/albumin/chitosan nanoparticles (S/A/CNP) on HepG2 cell line. The diameter of S/A/CNP was (5 ± 0.01) nm. The IC
was 180.4 nM and 47.6 nM for Strigol1 and S/A/CNP, respectively, after incubation for 24 h with HepG2 cells. By increasing the concentration of S/A/CNP, there was chromatin condensation, degranulation in the cytoplasm and shrinking in cell size indicating pro-apoptotic activity. Metabolomics profiling of the exposed cells by LC/MS/MS revealed that S/A/CNP up-regulated epigenetic intermediates (spermine and spermidine) and down-regulated energy production pathway and significantly decreased glutamine (P < 0.001). These findings demonstrated that S/A/CNP has anti-proliferative, apoptotic effects and modulate energetic, and epigenetic metabolites in the hepatocellular carcinoma cell line (HepG2).</abstract><cop>France</cop><pmid>34352718</pmid><doi>10.1016/j.biopha.2021.111960</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1950-6007 |
| ispartof | Biomedicine & pharmacotherapy, 2021-10, Vol.142, p.111960 |
| issn | 1950-6007 1950-6007 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2559430674 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Apoptosis - drug effects Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Cell Proliferation - drug effects Cell Survival - drug effects Chitosan - chemistry Chromatography, Liquid Down-Regulation - drug effects Hep G2 Cells Humans Inhibitory Concentration 50 Lactones - administration & dosage Lactones - pharmacology Liver Neoplasms - drug therapy Liver Neoplasms - genetics Metabolomics Nanoparticles Particle Size Serum Albumin, Human - chemistry Tandem Mass Spectrometry Up-Regulation - drug effects |
| title | Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T06%3A26%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strigol1/albumin/chitosan%20nanoparticles%20decrease%20cell%20viability,%20induce%20apoptosis%20and%20alter%20metabolomics%20profile%20in%20HepG2%20cancer%20cell%20line&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Al-Malki,%20Abdulrahman%20L&rft.date=2021-10&rft.volume=142&rft.spage=111960&rft.pages=111960-&rft.issn=1950-6007&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2021.111960&rft_dat=%3Cproquest_pubme%3E2559430674%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2559430674&rft_id=info:pmid/34352718&rfr_iscdi=true |